Practical aspects of pulsatile gonadotropin-releasing hormone administration.
Pulsatile administration of gonadotropin-releasing hormone represents a major advance in the treatment of anovulation in women who fail to ovulate with clomiphene citrate and is an alternative for many women who currently receive human menopausal gonadotropin. Four issues must be addressed before administering pulsatile gonadotropin-releasing hormone: (1) safety, (2) efficacy, (3) convenience, and (4) cost. Each of these issues will be affected by the three major decisions a physician makes with gonadotropin-releasing hormone therapy: (1) patient selection, (2) route of administration, and (3) dose of gonadotropin-releasing hormone. The ideal candidate for gonadotropin-releasing hormone therapy is a patient with an absence of endogenous pulsatile gonadotropin-releasing hormone, as seen in hypothalamic amenorrhea. Although women with polycystic ovarian disease can be treated with pulsatile gonadotropin-releasing hormone, a decreased ovulation rate should be expected. The route of administration, intravenous or subcutaneous, and the degree of monitoring can be tailored by the physician to fit each patient's needs. Pulsatile gonadotropin-releasing hormone therapy is a safe, effective, convenient, and economical alternative to human menopausal gonadotropin for ovulation induction in women resistant to clomiphene.
Schriock
E D
ED
Department of Obstetrics and Gynecology, University of Tennessee, Memphis.
D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy / Q000209:etiology; D003365:Costs and Cost Analysis; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007027:Hypothalamic Diseases / Q000150:complications / Q000188:drug therapy; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy; D011247:Pregnancy; D013997:Time Factors
D007987:Gonadotropin-Releasing Hormone